Trulieve secures Connected rights: what it means for Trulieve Cannabis stock

Published on 10/07/2026 at 00:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Connected rights cover Florida and Texas on September 28, 2026. Trulieve Cannabis stock sits within a USD 4.62 to USD 13.28 52-week range.

TRUL, US89790E1064, Illustration mit AI erstellt.

Trulieve Cannabis (ISIN US89790E1064) secured exclusive rights to produce and sell Connected and Alien Labs cannabis products in Florida and Texas on September 28, 2026. The agreement gives Trulieve Cannabis stock a concrete expansion angle, but the Texas rollout remains subject to final licensing and regulatory approvals, according to Yahoo Finance.

What the licensing means

The perpetual, royalty-free license covers Connected's genetics, trademarks and proprietary know-how. Trulieve can cultivate, manufacture and commercialize the branded products in Florida and Texas, while the agreement also gives it an option to negotiate rights in additional expansion markets.

The Florida relationship builds on an existing channel: Trulieve has supplied Alien Labs and Connected products there since 2022. The Texas opportunity is more conditional because the company still needs final approvals before introducing the brands, a distinction that limits the immediate financial read-through.

Second-quarter figures show the trade-off

Trulieve generated USD 270.95 million of revenue in the second quarter of 2026, down 10.31 percent from USD 302.09 million in the second quarter of 2025. Markets Insider reported that the company also posted a GAAP net loss of USD 406.06 million, compared with a GAAP net loss of USD 13.78 million a year earlier.

The loss was far larger than the prior-year figure, so the licensing agreement must be judged against both growth potential and recent earnings pressure. The company ended the second quarter with USD 325.42 million in cash, while operating cash flow was USD 53.10 million, according to the standardized quarterly financial statements.

Results date adds a near-term test

Trulieve will release its third-quarter 2026 results before a conference call scheduled for November 5, 2026, at 8:30 a.m. ET. Chairman and CEO Kim Rivers and CFO Jan Reese are scheduled to discuss the results, as StockTitan reported on October 6, 2026.

That date gives the market a defined checkpoint for assessing whether new licensing activity can offset the second-quarter revenue decline. The NYSE listing uses ticker TRLV, according to TradingView.

Market value frames the risk

Trulieve Cannabis had a market capitalization of USD 1.8 billion as of October 6, 2026. Its 52-week range was USD 4.62 to USD 13.28, placing the valuation between a low base and a substantially higher yearly peak.

The further course of trading is shown by the continuously updated real-time quote of Trulieve Cannabis stock.